Cargando…
The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis
SIMPLE SUMMARY: Melanoma is an aggressive form of skin cancer and the leading cause of skin cancer-related deaths. Current therapies, including those targeting oncogenic pathways and immunotherapies, provide therapeutic benefits to only a subset of melanoma patients. Therefore, more options for ther...
Autores principales: | Mason, Lawrence David, Chava, Suresh, Reddi, Kiran Kumar, Gupta, Romi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582741/ https://www.ncbi.nlm.nih.gov/pubmed/34771678 http://dx.doi.org/10.3390/cancers13215516 |
Ejemplares similares
-
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis
por: Chava, Suresh, et al.
Publicado: (2021) -
Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis
por: Chava, Suresh, et al.
Publicado: (2022) -
Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth
por: Chava, Suresh, et al.
Publicado: (2022) -
Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells
por: Reddi, Kiran Kumar, et al.
Publicado: (2022) -
472 Indiana CTSI Think Tank Program
por: Garcia, Kara, et al.
Publicado: (2022)